OneSource Specialty Pharma Share Price Gains Over 8% After Q2 FY27 Earnings Results: Total Income Up 36.5% YoY

On October 27, 2026, OneSource Specialty Pharma Limited announced its unaudited consolidated financial results for the quarter ending September 30, 2026, as per the exchange filings.  

The company reported a total income of ₹517.20 crore, marking a 36.5% increase compared to the same quarter in the previous year. Net profit for the quarter surged 448.2% year-on-year to ₹57.48 crore. 

OneSource Specialty Pharma Q2 FY27 Earnings Results 

In the September 2026 quarter, OneSource Specialty Pharma Limited achieved a total income of ₹517.20 crore, up from ₹378.80 crore in the same period last year. This represents a 36.5% year-on-year growth.  

The company's net profit also saw a substantial increase, rising to ₹57.48 crore from ₹10.48 crore a year ago, reflecting a 448.2% growth. 

Sequentially, the company's total income increased by 14.2% from ₹452.82 crore in the June 2026 quarter. Net profit also grew by 130.0% from ₹25.00 crore in the previous quarter. 

Half-Year Financial Overview 

For the half-year period ending September 30, 2026, OneSource Specialty Pharma Limited reported a total income of ₹970.02 crore, up 36.4% from ₹711.34 crore in the corresponding period of the previous year.  

Net profit for the half-year period increased by 700.9% year-on-year to ₹82.48 crore, compared to ₹10.30 crore in the previous year. 

Operational Highlights 

The company's operational performance was driven by new drug-device combination capacity and strong master services agreement execution.  

OneSource successfully commercialised 12 new products across North America, Latin America, and the MENA regions during the quarter.  

The company also reported a consolidated EBITDA of ₹163.30 crore, a 53% year-on-year increase, with an EBITDA margin of 31.6%. 

Read More: Landmark Cars Share Price in Focus; Signs Dealership Agreements with JSW Motors! 

Strategic Developments 

OneSource Specialty Pharma Limited has expanded its capacity by commercialising its second cartridge filling line, with plans to ramp up commercial volumes. The company has also completed factory acceptance testing for a third line.  

Additionally, OneSource onboarded a major United States biotechnology partner and completed 11 regulatory inspections and customer quality audits. 

OneSource Specialty Pharma Share Price Performance 

As of October 27, 2026, at 10:55 AM, OneSource Specialty Pharma share price on NSE was trading at ₹1,509.80, up by 8.05% from the previous closing price. 

Conclusion 

OneSource Specialty Pharma Limited reported a total income of ₹517.20 crore for Q2 2026, up 36.5% YoY, and a net profit of ₹57.48 crore, up 448.2% YoY. The half-year total income reached ₹970.02 crore, with a net profit of ₹82.48 crore, marking a 700.9% YoY increase. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.